MedTrace Logo

Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile Dysfunction

NCT03518333 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-06-24

No results posted yet for this study

Summary

This clinical study is designed to investigate the safety and potential ability of relocated autologous SVF (stromal vascular fraction) to restore erectile function in men with ED (erectile dysfunction).

Conditions

Interventions

DEVICE

Injection of adipose derived cells into penis

Injection of Icellator-derived cells

Sponsors & Collaborators

  • Tissue Genesis

    lead INDUSTRY

Principal Investigators

  • Paul Kosnik, PhD · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-03-01
Completion
2023-09-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03518333 on ClinicalTrials.gov